MYCODE®

Geisinger

Results reported

June 1, 2026

7,167 patient-participants have received results* from the Genomic Screening and Counseling Program

For the latest results, see **geisinger.org/MyCode-results.**

350,000+ participants have made the success of MyCode possible

Summary of results reported by category

	Total	Percentage
Cardiovascular risk	3,275	45%
Cancer risk	2,727	38%
Other**	1,263	17%

Breakdown of results reported

Risk Condition	Patients per condition	Gene	Patients per gene
Cardiovascular risk			
Familial hypercholesterolemia§ (early heart attacks and strokes)	897	*APOB*	285
		LDLR	612
Hereditary transthyretin amyloidosis (buildup of amyloid in the body, can lead to heart and nervous system disease)	267	*TTR*	267
Heritable thoracic aortic disease (genetic predisposition to weakening of the wall of the aorta, leading to swelling and sometimes rupture)	62	*ACTA2*	62
Inherited arrhythmias (irregular heartbeat with risk for cardiac arrest)	523	*KCNH2*	58
		KCNQ1	290
		RYR2	1
		SCN5A	174

(continued on next page)

June 1, 2026

MyCode® results reported *(continued)*

7,167 patient-participants have received results*
from the Genomic Screening and Counseling Program

Risk Condition	Patients per condition	Gene	Patients per gene
Cardiovascular risk *(continued)*			
Inherited cardiomyopathies (diseases of the heart muscle with dangerous complications)	1,523	*BAG3*	3
		DSC2	78
		DSG2	92
		DSP	118
		FLNC	80
		LMNA	35
		MYBPC3	277
		MYH7	124
		MYL2	11
		MYL3	8
		PKP2	118
		PRKAG2	3
		RBM20	1
		TNNI3	40
		TNNT2	10
		TPM1	6
		TTN	519
Cancer risk			
Familial adenomatous polyposis (intestinal polyps and early colon cancer)	85	*APC*	85
Hereditary breast and ovarian cancer§ (early breast, ovarian, prostate, pancreatic and other cancers)	1,307	*BRCA1*	458
		BRCA2	849
Hereditary pheochromocytomas and paragangliomas (tumors that can release extra hormones and, rarely, become cancer)	167	*SDHAF2*	15
		SDHB	72
		SDHC	30
		SDHD	14
		TMEM127	36
Li-Fraumeni syndrome (early breast, soft tissue, brain, adrenal and other cancers)	31	*TP53*	31

(continued on next page)

June 1, 2026

MyCode® results reported *(continued)*

7,167 patient-participants have received results*
from the Genomic Screening and Counseling Program

Risk Condition	Patients per condition	Gene	Patients per gene
Cancer risk *(continued)*			
Lynch syndrome§ (early colon, uterine and other cancers)	722	*MLH1*	63
		MSH2	51
		MSH6	314
		PMS2	294
Multiple endocrine neoplasia type 1 (tumors that can release extra hormones and, rarely, become cancer)	26	*MEN1*	26
Multiple endocrine neoplasia type 2 (early thyroid cancer)	149	*RET*	149
***MUTYH*-associated polyposis** (intestinal polyps and early colon cancer)	9	*MUTYH*	9
Neurofibromatosis, type 2 (noncancerous tumors in nervous system)	1	*NF2*	1
***PALB2*-related cancer risk** (early onset breast, pancreatic, and ovarian cancers)	212	*PALB2*	212
Peutz-Jeghers syndrome (early breast, colon, pancreatic and other cancers)	2	*STK11*	2
Retinoblastoma (early eye cancer)	9	*RB1*	9
Von Hippel-Lindau syndrome (early kidney cancer and benign tumors of the brain, eye, pancreas and adrenal gland)	4	*VHL*	4
Wilms tumor (malignant kidney tumor)	3	*WT1*	3
Miscellaneous phenotypes			
Biotinindase deficiency (buildup of a B vitamin in the body, can cause issues with the nervous system)	3	*BTD*	3
Fabry disease (enzyme defect leading to damage of blood vessels in the skin and cells in the kidneys, heart, and nervous system)	14	*GLA*	14

(continued on next page)

June 1, 2026

MyCode® results reported *(continued)*

7,167 patient-participants have received results*
from the Genomic Screening and Counseling Program

Risk Condition	Patients per condition	Gene	Patients per gene
Miscellaneous phenotypes *(continued)*			
Hereditary hemochromatosis (too much iron in blood, can lead to liver and heart problems)	648	*HFE*	648
Hereditary hemorrhagic telangiectasia (abnormal blood vessel formation in skin, mucous membranes, lungs, liver and brain)	63	*ACVRL1*	18
		ENG	45
Juvenile polyposis (intestinal polyps, cancer of the intestine, including colon)	6	*BMPR1A*	6
Juvenile polyposis / hereditary hemorrhagic telangiecstasia (intestinal polyps, cancer of the intestine, including colon/abnormal blood vessel formation in skin, mucous membranes, lungs, liver & brain)	6	*SMAD4*	6
Loeys-Dietz syndrome (weakening of the wall of the aorta, leading to swelling and sometimes rupture)	16	*SMAD3*	10
		TGFBR1	2
		TGFBR2	4
Malignant hyperthermia (life-threatening condition usually triggered by exposure to certain drugs used for general anesthesia)	321	*RYR1*	319
		CACNA1S	2
Marfan syndrome (connective tissue disease that can cause heart, eye, and skeletal problems)	39	*FBN1*	39
Maturity-onset diabetes of the young (MODY) (Diabetes in the teens or early adulthood)	18	*HNF1A*	18
Ornithine transcarbamylase deficiency (buildup of ammonia in the blood, can cause altered mental status and seizures)	4	*OTC*	4
Pompe disease (buildup of glycogen which could cause muscle problems throughout the body)	20	*GAA*	20
***PTEN* hamartoma tumor syndrome** (early breast, thyroid, uterine and other cancers, with intellectual disability in some cases)	28	*PTEN*	28

(continued on next page)

June 1, 2026

MyCode® results reported *(continued)*

7,167 patient-participants have received results*
from the Genomic Screening and Counseling Program

Risk Condition	Patients per condition	Gene	Patients per gene
Miscellaneous phenotypes *(continued)*			
Retinopathy (gradual vision loss, can lead to blindness)	1	*RPE65*	1
Tuberous sclerosis (multiple types of benign tumors)	35	*TSC1*	10
		TSC2	25
Vascular Ehlers-Danlos syndrome (disease of the connective tissues, including arteries and muscles, that can increase the risk for health complications, such as rupture of arteries)	24	*COL3A1*	24
Wilson disease (too much copper in the body, can cause liver disease and nervous system issues)	12	*ATP7B*	12
Totals[†,‡]	7,265		7,265

[§]CDC Tier 1 Condition

*Number of patient-participants with reported results and the number per gene variant/condition may not be equal due to the possibility of a participant having more than one result.

** Other - Includes conditions with metabolic presentation or syndromic cancer or cardiovascular risk

[†]Includes some patients (~12%) already aware of their genomic result from clinical genetic testing. The process of clinical confirmation and disclosure may be modified for these patients

[‡]The gene list designated for return has shifted over time (PMID: 33576083). Totals include fewer than 10 results in genes no longer on the return list.

Geisinger